On Demand

Non-invasive point of care  fibrosis assessment is central to disease management in viral hepatitis. Today’s noninvasive diagnostic tools support the ability to accurately and painlessly quantify liver health in both the treatment and post-treatment patient. These capabilities can be applied to assessment of treatment need, quantify risk of HCC and portal hypertension and monitor therapeutic response post SVR. 

 

Attendees Will

  • Understand the role of non-invasive diagnostics in evaluating viral hepatitis patients
  • Learn the strengths and weaknesses of primary diagnostic tools in each disease state
  • Understand the importance of fibrosis quantification based risk stratification
On Demand

Non-invasive testing (NIT) is an important and growing field which provides the ability to inexpensively and accurately assess liver fibrosis and steatosis. The role on NIT in liver disease assessment is rapidly evolving to accommodate the needs of NAFLD-NASH disease management.

In this one hour interactive presentation, Dr. Harrison will review the primary oral presentations and abstracts relating to the diagnosis and monitoring of NAFLD through non-invasive testing (NIT) at the point of care, from this years AASLD Liver Meeting.

On Demand

FibroScan applications in Non-Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) presented by Dr. Stephen Harrison.

On Demand

Sponsored by the Chronic Liver Disease Foundation (CLDF) Dr. Ken Cusi from the University of Florida discusses fatty liver disease in patients with type 2 diabetes.

On Demand

Dr. Nid Afdhal reviews liver stiffness and CAP assessments with FibroScan across the key etiologies of liver disease.

On Demand

In this presentation, Dr. Dietrich will review the AGA guidelines as they relate to Elastography and managing chronic liver disease.

On Demand

Learn about the new MyFibroScan application through an interactive walkthrough.

On Demand

This webinar will provide perspectives on the clinical considerations and patient management strategies for HCV patients with NAFLD - NASH comorbidity.

On Demand

Fatty liver disease in pediatric and adolescent patients with Dr. Miriam B. Vos from Emory University

On Demand

In this webinar, internationally renowned liver disease specialist, Dr. Michael Charlton, provides insights on the impact the fatty liver epidemic will have on donor demand, donor supply and transplant demand. The presentation includes strategies on how the active liver transplant center can prepare for these challenges.

On Demand

In the first installment of a four part educational webinar series, dedicated to furthering education and awareness on Non-Alcoholic Fatty Liver Disease we welcome guest speaker Dr. Zobair Younossi, the Professor of Medicine for Virginia Commonwealth University and Inova Campus. Dr. Younossi will provide an overview of the Epidemiology and Pathophysiology of NAFLD & NASH.

On Demand

The following educational webinar series is dedicated to furthering education and understanding of Non-Alcoholic Fatty Liver Disease. 

 

Each webinar episode is presented by a key opinion leading expert for the topic. The webinars are scheduled to build knowledge sequentially and in the second webinar of the NAFLD series, we welcome Dr. Mazen Noureddin, Director of the Fatty Liver Program at Cedars Sinai Medical Center. Dr. Noureddin will provide his unique insight into the future challenges and solutions of NAFLD – NASH.

On Demand

The following educational webinar series is dedicated to furthering education and understanding of Non-Alcoholic Fatty Liver Disease. 

Each webinar episode is presented by a key opinion leading expert for the topic. The webinars are scheduled to build knowledge sequentially and in the third episode of the NAFLD series, we welcome Dr. Stephen Harrison, Medical Director of Pinnacle Clinical Research. In this presentation, Dr. Harrison will discuss some of the treatment outlooks as it relates to patients with NAFLD - NASH.